Cannabinoids are the chemical compounds of the cannabis plant. Today, scientists know 113 types of cannabinoids. All of them have a broad range of properties and functions. Researchers are mostly focused on studying the two main cannabinoids—THC and CBD. However, the rest 111 compounds also have some peculiar effects on our bodies.
As a person involved in the weed world one or another way, you probably know that THC is the psychoactive part of the plant and is responsible for the high effect. CBD, in its turn, is mostly valued for its enormous medical benefits and its non-psychoactive nature. This compound is the main object of the research of the therapeutic applications of marijuana. Until lately, CBD had been the most prospective part of the plant. However, the further scientists search, the more new compounds appeal to them.
A few years ago, a groundbreaking study was conducted on the effects of CBD's cousin, cannabidivarin. Also known as CBDV, this chemical was isolated almost 50 years ago but was not fully examined until recently. The study showed that CBDV prevented seizures in rats. Now, the British pharmaceutical company GW Pharma intends to conduct clinical trials involving patients with epilepsy. The company already leads trials on CBD in Australia. GW Pharma's specialists research the effectiveness of their CBD product Epidiolex on children suffering from epilepsy disorders.
The pharmaceutical giant plans to conduct a CBDV study in Australia as well. The governments of both countries are supportive and provide the necessary funding. The government's involvement in the process makes Australia the leader in the world's medical cannabis research.
One of the most problematic issues of the medical studies is balancing the beneficial impact of chemical compounds and their side effects. All patients respond in their own way to different kinds of treatment, especially children. Sometimes, the cost of therapy may outweigh its benefits. Epilepsy is one of those conditions that are the most challenging. There are very few anti-epileptic drugs that do not cause side effects.
But how does marijuana help epilepsy? CBD is one of the compounds that have almost no adverse side effects. Early research suggests that it may help children with the drug-resistant forms of epilepsy. CBDV may be another alternative for the treatment. The element has great potential, and future trials may lead to a breakthrough in the usage of medical marijuana for epilepsy. CBDV can turn out to be the best tolerated drug.
In 2014, the early stage of the trials showed that cannabinoids-based treatment was well-tolerated even at the highest tested dose. Besides, there were no serious adverse events.
The results of the trials will show us the real way CBD and CBDV influence our bodies and the differences in their effects. Moreover, the success of the study may turn the attention of the world to other minor compounds of the cannabis plant that have been neglected before.